Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OFA vs OBA in VATS Lobectomy for NSCLC
NCT05172739Phase 4Recruiting
- Sponsor
- University of Crete
- Start
- Oct 2021
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dexmedetomidine, lidocaine and ketamine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of Crete. Primary endpoints: Neutrophil to Lymphocyte ratio, Interleukin-6 and 6 more. Started Oct 2021; status: recruiting.
02
Drugs
dexmedetomidinelidocaineketamine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05172739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05172739.